

Risperdal Consta® (risperidone) - First-time generic

- On December 12, 2023, <u>Teva launched</u> an <u>AB-rated</u> generic version of Janssen's <u>Risperdal</u> Consta (risperidone) long-acting intramuscular injection.
- Risperdal Consta is approved for the treatment of schizophrenia and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder.
- Risperidone is also available generically as a <u>tablet</u>, <u>oral solution</u>, and <u>orally disintegrating tablet</u>, and brand extended-release injectable suspension (<u>Perseris®</u>, <u>Rykindo®</u>, <u>Uzedy®</u>).
 - The tablet, oral solution, and orally disintegrating tablet carry the same indications as Risperdal Consta and are also approved for treatment of irritability associated with autistic disorder.
 - Perseris and Uzedy are approved for the treatment of schizophrenia in adults.
 - Rykindo carries the same indications as Risperdal Consta.
- Risperdal Consta carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.